The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAston Martin Lagonda Regulatory News (AML)

Share Price Information for Aston Martin Lagonda (AML)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 154.30
Bid: 154.40
Ask: 155.20
Change: -1.70 (-1.09%)
Spread: 0.80 (0.518%)
Open: 157.40
High: 157.70
Low: 154.30
Prev. Close: 156.00
AML Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Satisfaction of Antitrust Conditions

26 Nov 2020 09:31

RNS Number : 6113G
Aston Martin Lagonda Global Hld PLC
26 November 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

 

26 November 2020

 

Aston Martin Lagonda Global Holdings plc

Announcement of satisfaction of the Antitrust Conditions in relation to the Strategic Cooperation Agreement

 

Further to the announcement on 27 October 2020 by Aston Martin Lagonda Global Holdings plc (the "Company" or "Aston Martin Lagonda") relating to the Strategic Cooperation Agreement, and the publication on 18 November 2020 of the combined prospectus and circular (the "Prospectus"), the Company is pleased to announce that the Antitrust Conditions set out in the Prospectus in relation to the Strategic Cooperation Agreement have now been satisfied. Accordingly, the Strategic Cooperation is now conditional only on approval by Shareholders of the Transaction Resolutions proposed at the General Meeting of the Company to take place on 4 December 2020, as convened by the notice of meeting set out in the Prospectus.

 

Shareholders are requested to refer to the letter of recommendation from the Executive Chairman, set out in Part 5 (Letter from the Executive Chairman of Aston Martin Lagonda Global Holdings plc) of the Prospectus, which details why the Board believes the Transaction and the Resolutions to be in the best interests of the Shareholders as a whole.

 

The defined terms set out in the Prospectus apply in this Announcement.

 

Enquiries

Investors and Analysts

Charlotte Cowley Director of Investor Relations +44 (0)7771 976764

charlotte.cowley@astonmartin.com

Media

Kevin Watters Director of Communications +44 (0)7764 386683

kevin.watters@astonmartin.com

Grace Barnie Corporate Communication Manager +44 (0)7880 903490

grace.barnie@astonmartin.com

Tulchan Communications

Harry Cameron and Simon Pilkington +44 (0)20 73534200

 

Barclays (Sponsor and Financial Adviser)

Derek Shakespeare +44 (0)20 7623 2323

Enrico Chiapparoli

Tom Macdonald

Darren Johnson

 

J.P. Morgan Cazenove (Financial Adviser)

Robert Constant +44 (0)20 7742 4000

James A. Kelly

Will Holyoak

 

IMPORTANT NOTICE

 

This announcement has been issued by and is the sole responsibility of the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purpose whatsoever on the information contained in this announcement or on its accuracy or completeness. The information in this announcement is subject to change.

 

This announcement is not a prospectus and is for information purposes only. Neither this announcement nor anything contained in it shall form the basis of, or be relied upon in conjunction with, any offer or commitment whatsoever in any jurisdiction.

 

A copy of the Prospectus is available on the Company's website at https://www.astonmartinlagonda.com/investors/October-2020-Placing. Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

 

This announcement does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States. None of the securities referred to in this announcement or in the Prospectus have been or will be registered under the US Securities Act of 1933 (the "Securities Act") or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from or in a transaction not subject to the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offer of any such securities in the United States. None of the securities referred to in this announcement or in the Prospectus, nor the Form of Proxy, this announcement or any other document connected with the matters discussed in this announcement or in the Prospectus has been or will be approved or disapproved by the United States Securities and Exchange Commission or by the securities commissions of any state or other jurisdiction of the United States or any other regulatory authority, and none of the foregoing authorities or any securities commission has passed upon or endorsed the merits of such securities or documents or the accuracy or adequacy of this announcement or any other such document. Any representation to the contrary is a criminal offence in the United States.

 

No offer or invitation to purchase or subscribe for, or any solicitation to purchase or subscribe for, any securities will be made in any jurisdiction in which such an offer or solicitation is unlawful. The information contained in this announcement is not for release, publication or distribution to persons in the United States or Australia, Canada, Japan or the Republic of South Africa, and should not be distributed, forwarded to or transmitted in or into any jurisdiction, where to do so might constitute a violation of local securities laws or regulations.

 

The distribution of this announcement into jurisdictions other than the United Kingdom may be restricted by law, and, therefore, persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws of such jurisdiction. In particular, subject to certain exceptions, neither this announcement nor the Prospectus should be distributed, forwarded to or transmitted in or into the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction where to do so might constitute a violation of local securities laws or regulations.

 

The contents of this announcement are not to be construed as legal, business, financial or tax advice. Each Shareholder or prospective investor should consult his, her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.

 

Notice to all investors

 

Barclays Bank PLC, acting through its investment bank ("Barclays"), which is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority, is acting exclusively for the Company and no one else in connection with the Admission of the Tranche 1 Consideration Shares and the Placing Shares and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Barclays nor for providing advice in relation to Admission of the Tranche 1 Consideration Shares and the Placing Shares or any transaction, matter or arrangement referred to in this announcement or in the Prospectus.

 

J.P. Morgan Securities plc (which conducts its UK investment banking business as "J.P. Morgan Cazenove") is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and Financial Conduct Authority. J.P. Morgan Cazenove is acting exclusively for the Company and no one else in connection with the Strategic Cooperation and will not be responsible to anyone other than Aston Martin Lagonda Global Holdings plc for providing the protections afforded to clients of J.P. Morgan Cazenove nor for providing advice to any person in relation to the Strategic Cooperation or any matter or arrangement referred to in this announcement or in the Prospectus.

 

None of Barclays or J.P. Morgan Cazenove, nor any of their respective subsidiaries, branches or affiliates, nor any of their respective directors, officers or employees owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Barclays or J.P. Morgan Cazenove in connection with this Announcement, any statement contained herein, or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGCBDBCDDDGGL
Date   Source Headline
28th Jul 20217:00 amRNSInterim results for the six months to 30 June 2021
26th Jul 20217:00 amRNSHolding(s) in Company
22nd Jul 20217:00 amRNSAdditional Listing
15th Jul 20217:00 amRNSAdditional Listing
8th Jul 20217:00 amRNSDirectorate Change
29th Jun 20212:00 pmRNSDirector/PDMR Shareholding
29th Jun 202110:45 amRNSTotal Voting Rights
22nd Jun 20217:00 amRNSCommencement of legal proceedings
16th Jun 20212:00 pmRNSDirector/PDMR Shareholding
15th Jun 202111:06 amRNSDirector/PDMR Shareholding
28th May 20219:30 amRNSTotal Voting Rights
25th May 20211:00 pmRNSResult of AGM
10th May 202111:00 amRNSDirector/PDMR Shareholding
6th May 20217:00 amRNS1st Quarter Results
29th Apr 20219:30 amRNSTotal Voting Rights
21st Apr 20219:30 amRNSNotice of AGM
19th Apr 20217:15 amRNSDeath of Non-Executive Director
6th Apr 20211:45 pmRNSDirector Declaration - Correction
6th Apr 20211:00 pmRNSDirector Declaration
30th Mar 202110:30 amRNSTotal Voting Rights
11th Mar 202111:34 amRNSAnnual Financial Report
3rd Mar 20212:00 pmRNSDirector/PDMR Shareholding
2nd Mar 20219:30 amRNSDirector/PDMR Shareholding
26th Feb 20219:30 amRNSTotal Voting Rights
25th Feb 20216:04 pmRNSIssue of Debt
25th Feb 202110:30 amRNSIssue of Debt
25th Feb 20217:00 amRNSFinal Results
19th Feb 20211:32 pmRNSDirectorate Change
28th Jan 202112:25 pmRNSTotal Voting Rights
28th Jan 20219:00 amRNSDirectorate Change
30th Dec 202010:00 amRNSTotal Voting Rights
29th Dec 20209:00 amRNSHolding(s) in Company
15th Dec 20209:30 amRNSDirector/PDMR Shareholding
10th Dec 202010:00 amRNSHolding(s) in Company
9th Dec 20204:43 pmRNSDirector/PDMR Shareholding - Replacement
9th Dec 20201:30 pmRNSDirector/PDMR Shareholding
9th Dec 20201:30 pmRNSHolding(s) in Company
9th Dec 20201:30 pmRNSHolding(s) in Company
9th Dec 20209:17 amRNSHolding(s) in Company
7th Dec 20207:00 amRNSAdmission of Placing and Consideration Shares
4th Dec 20209:51 amRNSResult of the General Meeting
30th Nov 202010:00 amRNSTotal Voting Rights
26th Nov 20209:31 amRNSSatisfaction of Antitrust Conditions
18th Nov 20201:40 pmRNSPublication of a Prospectus
13th Nov 20203:25 pmRNSDirectorate Change
5th Nov 20202:00 pmRNSDirector/PDMR Shareholding
30th Oct 20205:25 pmRNSPricing of Senior Secured Notes
30th Oct 20203:30 pmRNSDirector/PDMR Shareholding
30th Oct 20203:08 pmRNSDirector/PDMR Shareholding
29th Oct 20201:17 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.